Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NVNO
ENVVENO MEDICAL CORPORATION
NASDAQ
$10.75
▼ DOWN 4.36% (-0.49)

KEY STATISTICS

Market Cap$177.41 K
52w High$35.70
52w Low$8.67
Dividend Yield—
Frequency—
P/E-0.43
Volume3.07K
Shares Out.16.50K

COMPANY

LEADERSHIP

Robert A. Berman
CHIEF EXECUTIVE
Robert A. Berman

COMPENSATION 2026

Salary$500,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$28,119
Total$1,161,132

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 31, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
33

UPCOMING EARNINGS

DateOct 30, 2026
DayFriday
Rev. Est.$2.25M
OCT
30
FRI

SPLIT RECORD

DATETYPERATIO
2026-01-20Reverse1:35
2020-11-30Reverse1:25

PRICE

$10.75 ▼ DOWN 4.36% (−$0.49)
OVERLAYS
$10.50$10.75$11.00$11.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM10.75

About enVVeno Medical Corporation

https://www.envveno.com ↗

enVVeno Medical develops bioprosthetic venous valve solutions, including the VenoValve and enVVe systems, to improve treatment for venous disease, with products designed for surgical and transcatheter implantation.

INDUSTRY

Medical - Devices

A PRODUCT ENVVENO MEDICAL CORPORATION IS KNOWN FOR

enVVe
enVVe

enVVe is a non-surgical, transcatheter venous valve designed to treat severe deep venous Chronic Venous Insufficiency, focusing on development and clinical trials after the FDA declined approval of their previous surgical product, VenoValve.

Revenue by Products

IconPRODUCTQ3-2018Q4-2018Q2-2019Q3-2019
Royalty Income$28.06K $28.06K $31.24K ▲$31.24K
Contract Research Related Party$13.6K $2.4K ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 6.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
44
TOP 12 OF 44 · RANKED BY POSITION SIZE
Perceptive Advisors LLC
1.8M sh · $564.3K
Kingdon Capital Management, L.L.C.
1.4M sh · $1.23M
Cm Management, LLC
1.3M sh · $401K
Vanguard Group Inc
861.2K sh · $780.24K
Act Capital Management, LLC
401.2K sh · $2.52M
Westside Investment Management, Inc.
212.8K sh · $192.82K
Geode Capital Management, LLC
201.2K sh · $64.57K
Gsa Capital Partners Llp
198.6K sh · $64K
Jpmorgan Chase & Co
182.3K sh · $165.2K
Jane Street Group, LLC
178.9K sh · $57.38K
Two Sigma Investments, LP
159.6K sh · $51.21K
Susquehanna International Group, Llp
154.5K sh · $139.97K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

★
DIRECTOR
Duhay Francis
Sale · 140 shares
2026-06-11
★
DIRECTOR
Duhay Francis
Sale · 140 shares
2026-03-12
★
OFFICER: CHIEF TECHNOLOGY OFFICER
Alavi Hamed
Sale · 50.0K shares
2025-12-16
★
OFFICER: SVP & CHIEF MEDICAL OFFICER
Glickman Marc H.
Sale · 100.0K shares
2025-12-16

SECTORS PEERS

PEERPRICE
AYTU$2.25COMPARE
COCH$0.69COMPARE
ADGM$0.51COMPARE
GOVX$0.72COMPARE
VVOS$0.22COMPARE
CODX$1.21COMPARE
AEMD$2.49COMPARE
PRPH$0.02COMPARE